Apogee Therapeutics, Inc.
APGEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeApogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary. The company carries a $6.19B market cap, placing it firmly in the mid-cap category. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
Market Cap
$6.19B
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-15.73
EPS (TTM)
$-4.33
EPS (Fwd)
$-5.22
ROE
-28.5%
ROA
-19.0%
Cash
$1.06B
Total Debt
$8.0M
Free CF
-$142.6M
52W Change
126.1%
Annual Financials
Cash vs Debt
Apogee Therapeutics, Inc. holds $1.06B in cash against $8.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$142.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -28.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.69 suggests APGE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, APGE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing APGE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.